Yi-Wen Yu1, Xue-Mei Zhao1, Yun-Hong Wang1, Qiong Zhou1, Yan Huang1, Mei Zhai1, Jian Zhang2. 1. State Key Laboratory of Cardiovascular Disease, Heart Failure Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. 2. State Key Laboratory of Cardiovascular Disease, Heart Failure Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. fwzhangjian62@126.com.
Abstract
BACKGROUND: Although the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) with or without heart failure (HF), the impact of SGLT2i on cardiac remodelling remains to be established. METHODS: We searched the PubMed, Embase, Cochrane Library and Web of Science databases up to November 16th, 2020, for randomized controlled trials reporting the effects of SGLT2i on parameters of cardiac structure, cardiac function, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level or the Kansas City Cardiomyopathy Questionnaire (KCCQ) score in T2DM patients with or without chronic HF. The effect size was expressed as the mean difference (MD) or standardized mean difference (SMD) and its 95% confidence interval (CI). Subgroup analyses were performed based on the stage A-B or stage C HF population and HF types. RESULTS: Compared to placebo or other antidiabetic drugs, SGLT2i showed no significant effects on left ventricular mass index, left ventricular end diastolic volume index, left ventricular end systolic volume index, or left atrial volume index. SGLT2i improved left ventricular ejection fraction only in the subgroup of HF patients with reduced ejection fraction (MD 3.16%, 95% CI 0.11 to 6.22, p = 0.04; I2 = 0%), and did not affect the global longitudinal strain in the overall analysis including stage A-B HF patients. SGLT2i showed benefits in the E/e' ratio (MD - 0.45, 95% CI - 0.88 to - 0.03, p = 0.04; I2 = 0%), plasma NT-proBNP level (SMD - 0.09, 95% CI - 0.16 to - 0.03, p = 0.004; I2 = 0%), and the KCCQ score (SMD 3.12, 95% CI 0.76 to 5.47, p = 0.01; I2 = 0%) in the overall population. CONCLUSION: The use of SGLT2i was associated with significant improvements in cardiac diastolic function, plasma NT-proBNP level, and the KCCQ score in T2DM patients with or without chronic HF, but did not significantly affect cardiac structural parameters indexed by body surface area. The LVEF level was improved only in HF patients with reduced ejection fraction.
BACKGROUND: Although the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) with or without heart failure (HF), the impact of SGLT2i on cardiac remodelling remains to be established. METHODS: We searched the PubMed, Embase, Cochrane Library and Web of Science databases up to November 16th, 2020, for randomized controlled trials reporting the effects of SGLT2i on parameters of cardiac structure, cardiac function, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level or the Kansas City Cardiomyopathy Questionnaire (KCCQ) score in T2DM patients with or without chronic HF. The effect size was expressed as the mean difference (MD) or standardized mean difference (SMD) and its 95% confidence interval (CI). Subgroup analyses were performed based on the stage A-B or stage C HF population and HF types. RESULTS: Compared to placebo or other antidiabetic drugs, SGLT2i showed no significant effects on left ventricular mass index, left ventricular end diastolic volume index, left ventricular end systolic volume index, or left atrial volume index. SGLT2i improved left ventricular ejection fraction only in the subgroup of HF patients with reduced ejection fraction (MD 3.16%, 95% CI 0.11 to 6.22, p = 0.04; I2 = 0%), and did not affect the global longitudinal strain in the overall analysis including stage A-B HF patients. SGLT2i showed benefits in the E/e' ratio (MD - 0.45, 95% CI - 0.88 to - 0.03, p = 0.04; I2 = 0%), plasma NT-proBNP level (SMD - 0.09, 95% CI - 0.16 to - 0.03, p = 0.004; I2 = 0%), and the KCCQ score (SMD 3.12, 95% CI 0.76 to 5.47, p = 0.01; I2 = 0%) in the overall population. CONCLUSION: The use of SGLT2i was associated with significant improvements in cardiac diastolic function, plasma NT-proBNP level, and the KCCQ score in T2DM patients with or without chronic HF, but did not significantly affect cardiac structural parameters indexed by body surface area. The LVEF level was improved only in HF patients with reduced ejection fraction.
Authors: Carlos G Santos-Gallego; Alvaro Garcia-Ropero; Donna Mancini; Sean P Pinney; Johanna P Contreras; Icilma Fergus; Vivian Abascal; Pedro Moreno; Farah Atallah-Lajam; Ronald Tamler; Anu Lala; Javier Sanz; Valentin Fuster; Juan Jose Badimon Journal: Cardiovasc Drugs Ther Date: 2019-02 Impact factor: 3.727
Authors: Kelly McHugh; Adam D DeVore; Jingjing Wu; Roland A Matsouaka; Gregg C Fonarow; Paul A Heidenreich; Clyde W Yancy; Jennifer B Green; Natasha Altman; Adrian F Hernandez Journal: J Am Coll Cardiol Date: 2019-02-12 Impact factor: 24.094
Authors: Mark H Drazner; J Eduardo Rame; Emily K Marino; John S Gottdiener; Dalane W Kitzman; Julius M Gardin; Teri A Manolio; Daniel L Dries; David S Siscovick Journal: J Am Coll Cardiol Date: 2004-06-16 Impact factor: 24.094
Authors: Elisabeth Kraigher-Krainer; Amil M Shah; Deepak K Gupta; Angela Santos; Brian Claggett; Burkert Pieske; Michael R Zile; Adriaan A Voors; Marty P Lefkowitz; Milton Packer; John J V McMurray; Scott D Solomon Journal: J Am Coll Cardiol Date: 2013-10-30 Impact factor: 24.094
Authors: Andrea Natali; Lorenzo Nesti; Iacopo Fabiani; Enrico Calogero; Vitantonio Di Bello Journal: Cardiovasc Diabetol Date: 2017-10-12 Impact factor: 9.951
Authors: David M Newland; Yuk M Law; Erin L Albers; Joshua M Friedland-Little; Humera Ahmed; Mariska S Kemna; Borah J Hong Journal: Pediatr Cardiol Date: 2022-08-10 Impact factor: 1.838
Authors: Sergio Gamaza-Chulián; Enrique Díaz-Retamino; Fátima González-Testón; José Carlos Gaitero; María José Castillo; Raquel Alfaro; Elías Rodríguez; Eva González-Caballero; Antonio Martín-Santana Journal: BMC Cardiovasc Disord Date: 2021-09-21 Impact factor: 2.298
Authors: Katarina Andelova; Barbara Szeiffova Bacova; Matus Sykora; Peter Hlivak; Miroslav Barancik; Narcis Tribulova Journal: Int J Mol Sci Date: 2022-01-26 Impact factor: 5.923
Authors: Bradley Sarak; Subodh Verma; C David Mazer; Hwee Teoh; Adrian Quan; Richard E Gilbert; Shaun G Goodman; Karan Bami; Otávio R Coelho-Filho; Vineeta Ahooja; Djeven P Deva; Vinay Garg; Sumeet Gandhi; Kim A Connelly; Andrew T Yan Journal: Cardiovasc Diabetol Date: 2021-10-04 Impact factor: 9.951